{"preliminary_commentary":{"by_channel":{"x_thread":9,"youtube":6,"podcast":6},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03148795\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["talazoparib"]],"indication":"metastatic castration-resistant prostate cancer with DNA repair alterations","name":"TALAPRO-1","nct_id":"NCT03148795","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=talapro-1-nct03148795. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Talazoparib 1 mg daily","label":"Talazoparib","type":"EXPERIMENTAL"}],"collaborators":["Medivation, Inc."],"completion_date":{"date":"2023-03-31","type":"ACTUAL"},"conditions":["Prostate Cancer"],"enrollment":{"count":128,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Talazoparib","otherNames":["MDV3800"],"type":"DRUG"}],"last_update":"2024-04-05","lead_sponsor":"Pfizer","official_title":"TALAPRO-1: A PHASE 2, OPEN-LABEL, RESPONSE RATE STUDY OF TALAZOPARIB IN MEN WITH DNA REPAIR DEFECTS AND METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO PREVIOUSLY RECEIVED TAXANE-BASED CHEMOTHERAPY AND PROGRESSED ON AT LEAST 1 NOVEL HORMONAL AGENT (ENZALUTAMIDE AND/OR ABIRATERONE ACETATE/PREDNISONE)","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2020-09-04","type":"ACTUAL"},"primary_outcomes":[{"measure":"Best Objective Response Rate (ORR)","timeFrame":"From first dose of study drug to best overall soft tissue response CR or PR (maximum duration of 25 months)"}],"references":[{"citation":"Castro E, Douglas Laird A, Mehra N, Dorff T, Zhao S, van Oort I, Gasparro D, Calabro F, Pignata S, Geczi L, Barthelemy P, Kilari D, Graf RP, Chen HC, Healy CG, Scagliotti GV, Chelliserry J, Kennedy D, Fizazi K, de Bono JS. Exploration of tumor genomics associated with prolonged benefit from or resistance to talazoparib monotherapy in patients with metastatic castration-resistant prostate cancer. Eur J Cancer. 2026 Sep 29;248:117079. doi: 10.1016/j.ejca.2026.117079. Online ahead of print.","pmid":"42849324","type":"DERIVED"},{"citation":"Mehra N, Fizazi K, de Bono JS, Barthelemy P, Dorff T, Stirling A, Machiels JP, Bimbatti D, Kilari D, Dumez H, Buttigliero C, van Oort IM, Castro E, Chen HC, Di Santo N, DeAnnuntis L, Healy CG, Scagliotti GV. Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses. Oncologist. 2022 Oct 1;27(10):e783-e795. doi: 10.1093/oncolo/oyac172.","pmid":"36124924","type":"DERIVED"},{"citation":"de Bono JS, Mehra N, Scagliotti GV, Castro E, Dorff T, Stirling A, Stenzl A, Fleming MT, Higano CS, Saad F, Buttigliero C, van Oort IM, Laird AD, Mata M, Chen HC, Healy CG, Czibere A, Fizazi K. Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial. Lancet Oncol. 2021 Sep;22(9):1250-1264. doi: 10.1016/S1470-2045(21)00376-4. Epub 2021 Aug 10.","pmid":"34388386","type":"DERIVED"}],"start_date":{"date":"2017-07-04","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer","url":"https://clinicaltrials.gov/study/NCT03148795"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/talapro-1-nct03148795"}